A practical reference on Tesamorelin: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-08-28. Anything still debated is marked as such rather than presented as settled.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
Insulin-like growth factor 1 is produced largely in the liver in response to growth hormone signaling. Its concentration shifts over days rather than minutes, which makes it practical for tracking changes across a study period. Interpretation still depends on age, nutritional status, and concurrent illness, all of which independently affect the marker. Reference ranges are therefore stratified, and comparisons are usually made within an individual over time rather than against a single population threshold.
Assays for these markers differ in calibration and antibody specificity, so results from different platforms are not always interchangeable. Reported values can shift when a laboratory changes method, even without any biological change. Studies that span long periods or multiple sites often need cross-validation of assays. This methodological variability is a recognized limitation when comparing findings across published reports, and it remains a topic of ongoing standardization work.
Macrolides Azithromycin Clarithromycin Erythromycin When taken independently, erythromycin has been shown to cause both QT prolongation and TdP. Erythromycin works inhibiting the CYP3A protein. Patients who have low CYP3A activity and are also concurrently taking other medications such as disopyramide, which can lead to QT prolongation and TdP. Fluoroquinolones Ciprofloxacin Levofloxacin Moxifloxacin
=== Analysis procedures === Shown below is a general procedure for monazite dating. The characteristics and procedures are different for each measurement tool, especially sample preparation and dating methods. Details of some common measurement tools are described in the section: Measurement tools.
=== HIV/AIDS === Ritonavir was initially approved in 1996 as a standalone antiretroviral protease inhibitor for the treatment of HIV-1 infection. Early pharmacokinetic and pharmacodynamic (PK-PD) observations revealed that while high-dose monotherapy (such as 600 mg twice daily) was effective at suppressing viral replication, it was associated with significant gastrointestinal toxicity and the rapid emergence of drug-resistant viral strains. However, researchers discovered that ritonavir is one of the most potent known inhibitors of the cytochrome P450 3A4 (CYP3A4) enzyme. Administering it at much lower doses (100–200 mg) significantly slows the metabolism of other co-administered drugs, boosting their plasma concentrations and extending their half-lives without causing severe side effects. Consequently, ritonavir's clinical application shifted; it is rarely used today for its independent antiviral activity. Instead, it is indicated almost exclusively as a pharmacokinetic enhancer (or "booster") in combination therapy alongside other, primary protease inhibitors (such as lopinavir, darunavir, or atazanavir) to improve their efficacy and reduce the pill burden for patients.
=== Socioeconomic status === People with low socioeconomic status often face many problems in the diagnosis and treatment of eating disorders like BED. These barriers include longer clinical waiting times, worse care, and less clinical investigation for individuals that "defy illness stereotypes". The costs associated with specialized mental health care pose another barrier for low socioeconomic status individuals. Furthermore, associated factors such as food insecurity and environmental stress have been shown to contribute to higher rates of eating disorders, such as BED, in these populations. Food security has been found to be a notable predictor of eating disorder behaviors. Low food security has been shown to increase the prevalence and frequency of binge eating. Researchers have been called on to reframe eating-related disorders to better fit low socioeconomic status populations and improve future investigations.
Sources: en.wikipedia.org
Pyroglutamate aminopeptidase is a type of enzyme that cleaves the peptide bond linking the N-terminal end of a polypeptide forming a cyclical lactam to the next amino acid residue. This cyclic structure protects the polypeptide from degradation but renders the protein difficult to analyze in the laboratory. Pyroglutamate aminopeptidase may be used to cleave the cyclical lactam and will therefore leave the next amino acid with a free N-terminal.
=== Pharmacokinetics === In a healthy person, the biological half-life of tetryzoline is approximately 6 hours, and it is excreted in urine, chemically unchanged, at least in part. In one study, 10 people were given two drops of 0.5 mg/mL of tetryzoline eye drops (0.025–0.05 mg) at 0 hrs, 4 hrs, 8 hrs, and 12 hrs. Within a 24-hour time window, since the last dose of tetryzoline, the blood serum concentration of tetryzoline in the test subjects was 0.068-0.380 ng/mL and the urine concentration was 13–210 ng/mL. Both the blood and the urine levels of tetryzoline reached their maximums approximately 9 hrs after the last dose. These fluid-concentration levels correspond to normal ocular use of tetryzoline; thus, greater concentrations of tetryzoline in the blood and the urine of the user can indicate misuse of the drug or of poisoning with the drug.
Lercanidipine (INN) is an antihypertensive (blood pressure lowering) drug. It belongs to the dihydropyridine class of calcium channel blockers, which work by relaxing and opening the blood vessels allowing the blood to circulate more freely around the body. This lowers the blood pressure and allows the heart to work more efficiently. This drug (trade name Zanidip, among others) acts more slowly than older dihydropyridines. It probably has fewer adverse effects, but a comparatively high potential for drug interactions. It was patented in 1984 and first approved for medical use in 1997. The FDA refused to approve the drug, and lercanidipine is not marketed in the United States.
==== Rookie of the Year Award and early career (1991–1993) ==== The Astros invited Bagwell to major league camp in spring training of 1991. Bagwell, expecting for the club to assign him to their Triple-A affiliate in Tucson, enthused them with his play. Because they, too, already had an established major leaguer at third base in Ken Caminiti, they approached Bagwell about shifting to first base, which he accepted. Having not previously played the position as a regular, Bagwell received a crash course, playing minor league games in the morning and Astros games in the afternoon until Opening Day. Observed The Sporting News: "Rookie Jeff Bagwell never played first base before this spring, but the position is his to lose. It's up to his bat." Thus, Bagwell made the major league club without an assignment to AAA, making the uncommon jump from AA to the major leagues, and made his major league debut on Opening Day. On May 6, he hit the ninth-ever upper-deck home run at Three Rivers Stadium off Bob Kipper in a seventh-inning pinch hit appearance, estimated at 456 feet (139 m). Bagwell hit .350 in September. He finished the year hitting .294 with 15 home runs and 82 RBI while leading the Astros in several offensive categories. He was named the 1991 National League (NL) Rookie of the Year, the first Astros player to win the award, Baseball America's Rookie of the Year, The Sporting News Rookie of the Year and postseason All-Star and on the Topps' Rookie All-Star Team. Bagwell's power hike piqued the curiosity of many baseball observers.
That Florey was not a pathologist was not overlooked; the Scottish pathologist Robert Muir declared: "There is no pathologist named Florey." The faculty board decided to take a chance on Florey, and he was appointed on 9 December. He took up the appointment in March 1932. The Floreys moved for the fourth time in five years, this time to a Victorian manor on 1 acre (0.40 ha) of ground about 1 mile (1.6 km) from the university, which later became student accommodation with the name "Florey Lodge". The chair came with a salary of £1,000 (equivalent to £57,000 in 2025) per annum, but there was no provision for an assistant. He took Kent with him anyway, eventually securing 50 shillings a week (equivalent to £141 in 2025) for him from the Medical Research Council (MRC). Guy's Hospital in London offered Florey a chair in pathology in February 1933. This caused alarm at the university, for it had recently lost two of its senior professors through the retirement of John Beresford Leathes and the departure of Edward Mellanby to become the secretary of the MRC. The university officials did not wish to lose Florey as well, and they raised his salary to £1,200 per annum to induce him to stay. The Sheffield Medical School was small, with only about fourteen students each year. The lack of a first-rate pathologist was remedied when Beatrice Pullinger joined the staff in January 1934, and she became Florey's ally in successfully lifting the standard of research and teaching in the department. While Florey's main interest was lysozyme, he pursued other lines of research as well.
Sources: en.wikipedia.org
=== Discovery === Darmstadtium was first discovered on November 9, 1994, at the Institute for Heavy Ion Research (Gesellschaft für Schwerionenforschung, GSI) in Darmstadt, Germany, by Peter Armbruster and Gottfried Münzenberg, under the direction of Sigurd Hofmann. The team bombarded a lead-208 target with accelerated nuclei of nickel-62 in a heavy ion accelerator and detected a single atom of the isotope darmstadtium-269:
=== Extraction === Bovine lactoferrin can be isolated from raw milk, colostrum, or whey using methods such as salt extraction, chromatography, and membrane filtration. Lactoferrin from a variety of species, including humans, can also be produced using transgenic organisms as a recombinant protein.
Commercial pepsin is extracted from the glandular layer of hog stomachs. It is a component of rennet used to curdle milk during the manufacture of cheese. Pepsin is used for a variety of applications in food manufacturing: to modify and provide whipping qualities to soy protein and gelatin, to modify vegetable proteins for use in nondairy snack items, to make precooked cereals into instant hot cereals, and to prepare animal and vegetable protein hydrolysates for use in flavoring foods and beverages. It is used in the leather industry to remove hair and residual tissue from hides and in the recovery of silver from discarded photographic films by digesting the gelatin layer that holds the silver. Pepsin was historically an additive of Beemans chewing gum by Dr. Edwin E. Beeman. The namesake of Pepsodent came from pepsin, designed to break down and digest food deposits on the teeth. Pepsin was an ingredient used in early Pepsodent toothpaste. Pepsin is commonly used in the preparation of F(ab')2 fragments from antibodies. In some assays, it is preferable to use only the antigen-binding (Fab) portion of the antibody. For these applications, antibodies may be enzymatically digested to produce either an Fab or an F(ab')2 fragment of the antibody. To produce an F(ab')2 fragment, IgG is digested with pepsin, which cleaves the heavy chains near the hinge region.
HbO2 + CO ⇌ Hb(CO) + O2 is established in the blood of cigarette smokers. Chelation therapy is based on the principle of using chelating ligands with a high binding selectivity for a particular metal to remove that metal from the human body. Complexes with polyamino carboxylic acids find a wide range of applications. EDTA in particular is used extensively.
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Binding stimulates cyclic AMP signaling and growth hormone secretion. This is the same receptor used by endogenous GHRH.